Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Monte Rosa Therapeutics, Inc.
Trials need funding. See this company's dilution risk and cash position.
- $38M upfront/ $2.1B totalOct 28, 2026MRT-6160 (DDY391)
- Phase 2Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Oral MRT-2359, Apalutamide
Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer +2
NCT07745361Enrollment25StartAug 2026Primary CompletionOct 2027est.CompletionApr 2028est. - Phase 1/2Active, not recruiting
Study of Oral MRT-2359 in Selected Cancer Patients
Oral MRT-2359, Oral MRT-2359
NSCLC, SCLC +6
NCT05546268Enrollment174StartOct 2022Primary CompletionMay 2026est.CompletionNov 2027est. - Phase 1Completed
First-in-human Study of MRT-6160 in Healthy Subjects
MRT-6160, Placebo
Healthy Volunteers
NCT06597799Enrollment108StartAug 2024Primary CompletionApr 2025CompletionApr 2025 - Phase 1Active, not recruiting
A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP
MRT-8102, Placebo
Healthy Volunteers, Elevated CRP
NCT07119125Enrollment100StartJun 2025Primary CompletionJul 2026est.CompletionJul 2026est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Recruiting | Oral MRT-2359, Apalutamide | NCT07745361 |
| Phase 1/2 | Active, not recruiting | Oral MRT-2359, Oral MRT-2359 | NCT05546268 |
| Phase 1 | Completed | MRT-6160, Placebo | NCT06597799 |
| Phase 1 | Active, not recruiting | MRT-8102, Placebo | NCT07119125 |